News

Article

Aurion Biotech completes dosing of all subjects in Phase 1/2 CLARA trial

The trial is evaluating AURN001, a combination cell therapy product comprised of neltependocel (allogeneic human corneal endothelial cells [CECs]) and Y-27632 for the treatment of corneal edema secondary to corneal endothelial dysfunction.

A dosing vial and syringe (Image Credit: AdobeStock/BillionPhotos.com)

(Image Credit: AdobeStock/BillionPhotos.com)

Aurion Biotech has announced all subjects in its Phase 1/2 CLARA trial of AURN001 (NCT06041256) have been dosed.

The company’s AURN001 is a combination cell therapy product comprised of neltependocel (allogeneic human corneal endothelial cells [CECs]) and Y-27632 for the treatment of corneal edema secondary to corneal endothelial dysfunction, intended to be administered to the eye as a one-time, intracameral injection.1,2

The CLARA Phase 1/2 is a prospective, multi-center, randomized, double-masked, parallel-arm cell dose-ranging clinical trial, evaluating the safety, tolerability, and efficacy of AURN001 for the treatment of corneal edema secondary to corneal endothelial dysfunction. The primary endpoint is a 15-letter improvement (3-line gain) from baseline in best-corrected visual acuity (BCVA) after 6 months.3 Three different doses of AURN001 are being evaluated (high, medium, and low).3

Ninety-seven patients have been randomized in the US and Canada. Patients were enrolled if they had a diagnosis of corneal edema secondary to corneal endothelial dysfunction and required surgery (full- or partial-thickness endothelial keratoplasty). Those who have pre-operative corneal epithelial, sub-epithelial, or stromal scarring or other opacity that is paracentral/central and visually significant were excluded.3

“Aurion Biotech is delighted that both enrollment and dosing in our Phase 1/2 trial are now complete, and that it happened more rapidly than we expected,” said Michael Goldstein, MD, MBA, President and Chief Medical Officer of Aurion Biotech. “We enrolled and dosed subjects in six months, which speaks to the deep interest among physicians and patients for our allogeneic cell therapy, as well as the potentially large, unmet need for our elegant, minimally invasive procedure to treat this sight-threatening disease.

References:
  1. AURION BIOTECH ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 1 / 2 CLINICAL TRIAL. Press release; April 30, 2024. Accessed April 30, 2024. https://aurionbiotech.com/aurion-biotech-announces-completion-of-enrollment-in-phase-1-2-clinical-trial/
  2. AURION BIOTECH ANNOUNCES FIRST CANADIAN SUBJECT DOSED IN PHASE 1 / 2 CLINICAL TRIAL. Press release; March 28, 2024. Accessed April 30, 2024. https://aurionbiotech.com/aurion-biotech-announces-first-canadian-subject-dosed-in-phase-1-2-clinical-trial/
  3. A Phase 1/​2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1) (CLARA). NCT06041256. https://clinicaltrials.gov/study/NCT06041256?tab=table

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.